Fund of the week: Novo Holdings

Overview and Investment Focus

Novo Holdings is not a typical corporate venture capital fund. It is the wholly owned holding and investment company of the Novo Nordisk Foundation — one of the largest philanthropic foundations in the world — and functions simultaneously as a controlling industrial shareholder, a multi-stage life science investor, a global buyout platform, and a sustainability-oriented growth investor. Incorporated in Copenhagen in 1999, Novo Holdings had Total Assets under Management of DKK 1,060 billion (€142 billion / ~$148 billion) as of year-end 2024, making it by a wide margin the largest CVC-affiliated investor in biopharma. Its Investment Portfolio generated a record 18% return in 2024, and total income and investment returns for the year reached DKK 60 billion (€8.0 billion). Since its founding, Novo Holdings has invested in more than 350 companies across the globe.

Investment Thesis: Novo Holdings operates under a dual mandate that distinguishes it from every other life science investor: generate attractive long-term returns, and deploy those returns to fund the Novo Nordisk Foundation's philanthropic grant programme. In 2024 alone, the Foundation awarded DKK 10 billion (€1.4 billion) in grants. The investment thesis across the life science portfolio is stage-agnostic — Novo Holdings invests from company creation through public market ownership — and its areas of focus span pharmaceuticals, biotechnology, medical technology, healthcare services, industrial biosolutions, and planetary health. Geographically, the firm covers North America, Europe, and Asia through offices in Copenhagen, London, Boston, San Francisco, Singapore, and Shanghai, with a new Mumbai office opening in 2025.

From Insulin Profits to a €142 Billion Institution

The origins of Novo Holdings trace to 1922, when Danish Nobel laureate August Krogh and his wife Marie travelled to North America to acquire the rights to manufacture insulin in Scandinavia. Krogh's promise to return profits from insulin sales to scientific and humanitarian purposes became the philosophical foundation for the Novo Nordisk Foundation, established in 1924. Decades of mergers and reorganisations among Danish insulin and enzyme companies ultimately produced the modern Novo Group: Novo Nordisk A/S (pharmaceuticals) and Novonesis A/S (formerly Novozymes, industrial biotechnology), both majority-controlled by Novo Holdings through its ownership of all preferred A-shares.

Novo Holdings itself was incorporated in 1999 as a holding and investment vehicle to manage the Foundation's growing assets. From an initial focus on direct Novo Group ownership and modest life science investments, the firm expanded methodically: building out a venture platform (then called Novo Ventures), adding a seed-stage company creation capability for Scandinavia, launching a growth equity team, and ultimately creating a full-scale principal investments buyout platform. The Catalent acquisition in December 2024 — a $16.5 billion all-cash take-private of one of the world's largest CDMOs — marked the largest healthcare buyout globally in 2024 and cemented Novo Holdings' position as a heavyweight in the life science private equity market, not merely a specialist venture fund.

In October 2025, Novo Holdings announced a board transition, with a new Chair (former CFO of Novonesis) and Vice Chair (CEO of Ambu A/S) installed effective November 2025.

Investment Architecture

Novo Holdings' most distinctive structural feature is the organisation of its life science activities into six distinct investment platforms, each targeting a different stage and sector of the life science value chain. These sit alongside a substantial Capital Investments division managing equities, fixed income, real estate, infrastructure, and private equity fund-of-funds. As of year-end 2024, Life Science Investments represented 59% of the total portfolio, with Capital Investments accounting for the remaining 41%.

Seed Investments creates and builds biotech companies in the Nordic region, combining an in-house SeedLab (wet lab infrastructure for early validation) with a network of Entrepreneurs-in-Residence. The Seed team finances companies from inception through commercial exit, without syndicating out control in early rounds. By year-end 2024, the Seed portfolio comprised 35 companies, with private investments valued at DKK 4.2 billion, 19% higher than at year-end 2023.

Venture Investments (operating through the Novo Ventures brand) is one of the largest life science venture operations globally, covering private and public biotech, medtech, and digital health investments in the US, Europe, and Asia. The team invests at Series A and later and takes active board positions. In 2024, Venture Investments deployed a record DKK 4.9 billion, including DKK 3.2 billion across 20 new investments.

Growth Investments targets commercial-stage companies in clinical diagnostics, industrial biotechnology, biologics supply chain, and healthcare IT, managing approximately €690 million in AUM across 11 portfolio companies at year-end 2024.

Principal Investments is the buyout and large-scale private equity platform, executing majority and significant minority acquisitions of established life science companies. Its portfolio reached DKK 99 billion at year-end 2024, driven primarily by the landmark Catalent transaction.

Planetary Health Investments targets industrial biotechnology and sustainability-oriented life science companies, reflecting the Foundation's mandate to address the green transition. The team deployed DKK 2.6 billion (€348 million) in 2024.

Asia Investments operates dedicated offices in Singapore and Shanghai, with a third office opened in Mumbai in 2025. The team deployed DKK 768 million ($107 million) in 2024, with notable positions in Manipal Hospitals and Qure.ai.

The Novo Group: The Engine Behind the Capital

Any analysis of Novo Holdings that ignores its role as the controlling shareholder of Novo Nordisk A/S and Novonesis A/S is fundamentally incomplete. Novo Holdings owns more than 25% of the ordinary share capital of Novo Nordisk and controls more than 70% of the votes through its ownership of all preferred A-shares. Dividends and share repurchases from Novo Nordisk and Novonesis — the primary sources of Novo Holdings' investable capital — totalled DKK 23 billion (€3.1 billion) in 2024 alone.

Novo Nordisk's ascent to one of Europe's most valuable companies, driven by the extraordinary commercial success of semaglutide-based GLP-1 therapies (Ozempic for diabetes, Wegovy for obesity), created a capital windfall that directly funded the most aggressive period of life science dealmaking in Novo Holdings' history. The Catalent acquisition itself was structured in part to serve Novo Nordisk's manufacturing capacity needs: three of Catalent's 50 global fill-finish sites in Anagni (Italy), Bloomington (USA), and Brussels (Belgium) were immediately sold on to Novo Nordisk for approximately $11 billion to support semaglutide production scale-up. This three-way transaction is a uniquely corporate-VC phenomenon — an investment that simultaneously serves the financial interests of the holding company and the industrial interests of its primary portfolio company.

Venture Portfolio — Key Active Investments

The Novo Ventures portfolio spans biotech (late preclinical and clinical), medtech, and digital health. The team serves on boards of directors at portfolio companies and draws on Novo Holdings' commercial and scientific network as a source of value-add beyond capital.

Notable Venture Exits (2024–2025)

Principal Investments Portfolio — Buyouts and Large-Scale Holdings

Principal Investments represents Novo Holdings' engaged ownership model applied to established life science businesses. At year-end 2024, the portfolio comprised 16 companies with a total value of DKK 99 billion.

Seed Investments — Company Creation in Scandinavia

The Seed platform is the closest analogue to a traditional venture creation model within Novo Holdings, and arguably one of the most overlooked aspects of the firm's architecture. Operating through the Novo SeedLab — a wet laboratory facility that can validate early experimental data and accelerate drug discovery — and a cohort of Entrepreneurs-in-Residence (EiRs), the Seed team originates companies from scratch in the Nordic ecosystem.

Recent seed-stage launches include Booster Therapeutics (Oct 2024, $15M seed; proteasome activators for neurodegeneration, co-led with Apollo Health Ventures), Hemab Therapeutics (bleeding disorders, now at Series C with $157M raised), and BACTOLIFE. The Seed portfolio raised DKK 3.9 billion (€523 million) from international investors in 2024 alone, demonstrating the team's ability to syndicate its internally created companies to global venture capital. The 35 active seed-stage companies represent a sustained pipeline of Nordic biotech talent being channelled into Novo Holdings' broader investment ecosystem.

Planetary Health Investments

Planetary Health Investments is the unit through which Novo Holdings is implementing what it calls the "green transition" of its portfolio — a deliberate expansion from human therapeutics into industrial biotechnology, sustainable food systems, and circular economy businesses. The team deployed DKK 2.6 billion (€348 million) in 2024 and manages a portfolio of 23 companies.

Representative investments include Matr Foods (€40M round, Oct 2025; alt-meat fermentation), Chromologics (€7M, Nov 2025; precision fermentation colorants as alternatives to synthetic dyes including Red No. 3), Blue Planet (Nov 2025; circular waste solutions in Asia), and REDUCED (fermentation-based natural food ingredients). The bioindustrial thesis rests on the convergence of microbiology, synthetic biology, and fermentation engineering as tools for replacing petrochemical-based industrial processes — an investment category where Novo Holdings' heritage in both industrial biotech (through Novonesis) and life science venture gives it genuine sectoral depth.

Portfolio Analysis

Novo Holdings' portfolio can be mapped across four distinct strategic clusters, each reflecting a deliberate capital allocation choice.

Life Science Infrastructure (CDMO, CRO, Drug Packaging): The Catalent acquisition is the clearest statement of a thesis that Novo Holdings has been building for years: that the manufacturing and services layer of the pharma value chain is structurally attractive, capital-efficient to improve, and closely aligned with the Foundation's purpose. The Catalent deal followed earlier Principal Investments positions in Clario (clinical trial technology) and SCHOTT Poonawalla (injectable packaging). Catalent's pending sale of three fill-finish sites to Novo Nordisk for $11 billion makes this the most structurally complex investment in Novo Holdings' history, blurring the line between financial investment and industrial strategy.

Clinical-Stage Biotech (Venture): The Venture portfolio reflects a concentrated thesis around late preclinical and clinical-stage assets across oncology (cell therapy, radiopharmaceuticals, T cell engagers), neurology (neurodegeneration, psychiatry), cardiomyopathy, immunology, and respiratory disease. Notable standouts in 2024 include Edgewise Therapeutics (up 175%, genetic heart disease and neuromuscular disorders), Vaxcyte (up 56%, 31-valent pneumococcal vaccine), and the exits via AstraZeneca (Amolyt, $1.05B) and Johnson & Johnson (Numab bispecific, $1.2B).

Nordic Biotech Creation (Seed): A consistent pipeline of founder-led Nordic biotechs across haematology, neurology, immunology, and dermatology, funded from inception and syndicated globally at Series A and B.

Planetary Health / Industrial Biotech: A deliberately diversified cluster spanning fermentation-based food ingredients, alternative proteins, circular waste solutions, and precision biology for agriculture — all benefiting from Novo Holdings' access to Novonesis's deep fermentation and industrial biotech expertise.

Asia Healthcare: Emerging as a standalone strategic priority. Novo Holdings invested in Manipal Hospitals, Medi Assist (pre-IPO), Qure.ai (AI diagnostics, Series D), AgNext (AI for sustainable agriculture), and Surya Hospitals. The opening of a Mumbai office in 2025 signals a multi-year commitment to India as the primary Asian growth market.

Strategic Differentiators

1. Permanent Capital from a Mission-Aligned Owner. Unlike conventional CVC funds — where capital originates from a parent company's balance sheet and can be withdrawn if the parent's priorities shift — Novo Holdings operates with effectively permanent capital generated by the Novo Nordisk Foundation's endowment and Novo Group dividends. In 2024, dividends and share repurchases from Novo Nordisk and Novonesis totalled DKK 23 billion. This structural feature allows Novo Holdings to hold investments through complete market cycles, support companies through prolonged development timelines, and execute large transactions (such as Catalent) that require multi-year commitment horizons.

2. Unrivalled Scale Among CVC Investors. With $148 billion in total assets and 382 investments since 1999, Novo Holdings is not merely the largest pharma-affiliated CVC investor — it operates at an entirely different scale from its nearest competitors. Novartis Venture Fund, Pfizer Ventures, Roche Venture Fund, and JJDC collectively manage a small fraction of Novo Holdings' AUM. This scale provides access to deal flow, co-investment relationships, and board influence that no other CVC in the sector can replicate.

3. Full Lifecycle Coverage. Novo Holdings can invest in a company from pre-seed (Seed Investments), through venture (Novo Ventures), growth equity (Growth Investments), and buyout (Principal Investments), all within a single institutional framework. For founders and management teams, this creates the possibility of a continuous institutional relationship across multiple funding rounds without competitive dynamics between investor vintages.

4. Novo Nordisk Strategic Adjacency. While Novo Holdings maintains formal independence from Novo Nordisk's commercial operations, the proximity is valuable in both directions. Portfolio companies gain access to one of the world's largest pharmaceutical distribution networks and deep expertise in regulatory, manufacturing, and clinical operations. Novo Holdings can source dealflow from companies that have entered commercial relationships with Novo Nordisk, and can structure transactions (as with Catalent) that simultaneously address Novo Nordisk's supply chain constraints.

5. Sectoral Depth in Industrial Biotech. Through decades of Novonesis ownership and the Planetary Health Investments initiative, Novo Holdings has built institutional expertise in fermentation science and industrial biotechnology that is not replicated by any other life science investor of comparable scale. This creates genuine information advantages when evaluating precision fermentation, biosolutions, and green chemistry companies.

Risks and Vulnerabilities

1. Concentration Around Novo Nordisk's Fortunes. Novo Holdings' investable capital is substantially derived from Novo Nordisk dividends. Novo Nordisk entered 2026 under significant pressure — increased competition from Eli Lilly in GLP-1 obesity therapies, pricing headwinds in the US market, and a CEO transition. The company has warned of sales and earnings declines of 5-13% in 2026. A sustained deterioration in Novo Nordisk's financial performance would directly reduce the capital available to Novo Holdings for new investments, with compounding effects across a portfolio that relies on continued follow-on support.

2. Catalent Integration Complexity. The $16.5 billion Catalent acquisition is the largest transaction in Novo Holdings' history by a wide margin. Catalent operates across more than 40 global sites, employs thousands of scientists and technicians, and is embedded as a critical supplier to much of the global biopharma industry — including Novo Nordisk's competitors in the GLP-1 space. Managing the three-way transaction (Novo Holdings acquires Catalent, sells three sites to Novo Nordisk, retains the rest as a going concern) while maintaining Catalent's relationships with its 1,500 active development programmes presents significant operational risk. Any perception among Catalent customers that their manufacturing programmes are subordinated to Novo Nordisk's interests could damage the CDMO's competitive position.

3. Corporate Venture Conflict of Interest. Novo Holdings' unique position — simultaneously a portfolio investor in companies that compete with Novo Nordisk and the controlling shareholder of Novo Nordisk itself — creates structural tension that no formal governance arrangement fully resolves. Investment decisions in GLP-1 competitors, diabetes technology companies, or obesity drug developers will always be viewed through the lens of potential conflict, regardless of the independence of Novo Holdings' investment teams.

4. Geographic Concentration in a Challenging Regulatory Environment. Novo Holdings' expansion into Asia, and particularly India, coincides with a period of significant geopolitical uncertainty in Asian supply chains and regulatory systems. The firm's Shanghai office and investments in Chinese agricultural technology companies face headwinds from US-China technology tensions and evolving Chinese domestic capital market restrictions.

5. Opaque Venture Performance Metrics. Novo Holdings publishes total AUM, Investment Portfolio returns, and headline transaction data, but does not report individual fund-level IRRs or vintage-year multiples for its venture activities. The firm's overall 18% Investment Portfolio return in 2024 is significantly influenced by Novo Nordisk's own stock performance and the Catalent transaction structure. Independent assessment of Novo Ventures' risk-adjusted returns relative to institutional venture benchmarks remains difficult for external observers.

Leadership

Kasim Kutay has served as CEO since September 2016, having previously spent 18 years at Morgan Stanley as Chair of the European Healthcare Group and later as Co-Head of Europe at Moelis & Co. The Executive Leadership Team comprises six members and the Board of Directors nine, with a new Chair and Vice Chair installed in November 2025.

Novo Holdings employs approximately 327 people across its global offices. The team is split roughly as follows:

The US team is weighted toward Venture Investments and Principal Investments (US buyout). The Copenhagen headquarters houses Seed Investments, corporate functions, Capital Investments, and senior leadership. London covers European venture and growth deal execution. The Asia offices, expanded with the Mumbai opening in 2025, remain the smallest but fastest-growing part of the team.

Recent Developments (2024–2026)

The twelve months from early 2025 through March 2026 have been among the most consequential in Novo Holdings' history.

The Catalent acquisition, announced in February 2024 and closed in December 2024 for $16.5 billion, simultaneously marked the largest healthcare buyout globally in 2024 and the most complex transaction Novo Holdings has ever executed. Each year, Catalent supplies approximately 70 billion doses of more than 7,000 products and assembles over 320,000 clinical supply patient kits across 1,200 clinical protocols — representing roughly 50% of all FDA new drug approvals over the past decade.

Also in December 2024, Novo Holdings completed the acquisition of Single Use Support, a DACH-region bioprocessing specialist, marking the firm's first buyout in the German-speaking market.

On the exits side, KabaFusion — a US home infusion therapy platform acquired in November 2022 — was sold to Nautic Partners in a transaction that closed in February 2026. Under Novo Holdings' ownership, KabaFusion nearly doubled in size. The sale price was approximately $2.2 billion, reflecting roughly 20x EBITDA.

In venture, 2025 brought the firm's most active CVC year on record by deal count, with Novo Holdings participating in 18 private venture rounds — more than any other tracked CVC investor, according to BioPharma Dive data. The Expedition Therapeutics Series A ($165M, COPD), Hemab Series C ($157M, bleeding disorders), Clasp Therapeutics Series A ($150M, immuno-oncology), and Veradermics Series C ($150M, dermatology) were among the most significant 2025 venture investments.

In October 2025, Clario — a clinical trials technology platform in the Principal Investments portfolio — agreed to be acquired by Thermo Fisher Scientific. And in November 2025, Novo Holdings divested its ~£370M stake in ConvaTec, a publicly listed medical device company.

The board transition in November 2025 (Lars Green as Chair, Britt Meelby Jensen as Vice Chair) marks the beginning of a succession from the founding generation of Novo Holdings leadership, coinciding with the launch of Strategy 2030 — a multi-year roadmap to operationally scale investment platforms and accelerate Planetary Health Investments.

Conclusion

Novo Holdings occupies a position that no other investor in life sciences can claim: a permanent-capital institution with a philanthropic mandate, controlling ownership of two of Europe's largest industrial biotechnology companies, a full-spectrum life science investment platform from seed to buyout, and more than $148 billion in assets generating a 10% trailing five-year return. The Catalent acquisition crystallised the firm's evolution from a specialist venture fund into a life science conglomerate investor with genuine industrial strategy capability. The 18% Investment Portfolio return in 2024 — its best-ever performance — was driven by the extraordinary financial performance of Novo Nordisk and the structural gains from the Catalent transaction.

The open questions are equally structural. Novo Nordisk's competitive position in the GLP-1 market is under serious pressure from Eli Lilly in 2026, with consequences for the dividend flows that sustain Novo Holdings' dealmaking capacity. The Catalent integration is a multi-year operational challenge of a complexity the firm has not previously managed. And the inherent conflict between a corporate parent's commercial interests and an investment platform's fiduciary obligations to portfolio companies will require continuous governance vigilance as the Novo Group's competitive dynamics intensify.

What Novo Holdings has built is less a fund than a permanent institution — one whose investment philosophy, philanthropic mandate, and industrial ownership structure are mutually reinforcing in ways that no purely financial investor can replicate. For the pharmaceutical royalty and life science financing markets, it represents the most important non-bank, non-sovereign institutional capital pool in the sector.

All information in this article was accurate as of the research date (March 2026) and is derived from publicly available sources including company press releases, SEC filings, regulatory announcements, and financial news reporting. Information may have changed since publication. This content is for informational purposes only and does not constitute investment, legal, or financial advice. The author is not a lawyer or financial adviser.